Evaluation of ACCS100 to Reduce Aflatoxin Exposure in Kenya
Launched by KENYA MEDICAL RESEARCH INSTITUTE · Jul 11, 2014
Trial Information
Current as of October 23, 2025
Completed
Keywords
ClinConnect Summary
Aflatoxins are harmful by-products of the molds Aspergillus flavus and A. parasiticus and are major contaminants of agricultural produce such as maize. Acute aflatoxin exposure (i.e., aflatoxicosis) can lead to jaundice, vomiting, abdominal pain, and liver failure, with documented fatality rates as high as 40%. Kenya experiences extreme aflatoxin exposure and fatal, recurring aflatoxicosis outbreaks. Numerous clinical trials have found heat processed calcium dioctahedral smectite clay \[i.e., Air Classified Calcium Silicate (ACCS100)\] to be safe and effective in binding to aflatoxin to dec...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult ≥18 years of age
- • Consumes corn- and/or peanut-derived foods at least four times per week
- • No plans to travel away from the household for more than one day in the next month
- Exclusion Criteria:
- • Women who may be pregnant
- • History of medical illnesses
- • Presence of protein or glucose in urine using chemstrip
- • Does not provide informed consent
About Kenya Medical Research Institute
The Kenya Medical Research Institute (KEMRI) is a leading health research organization dedicated to advancing medical knowledge and improving public health in Kenya and beyond. Established to conduct high-quality research in various areas, including infectious diseases, non-communicable diseases, and health systems, KEMRI plays a pivotal role in translating scientific findings into impactful health policies and interventions. With a strong commitment to ethical standards, collaboration, and community engagement, KEMRI actively sponsors and conducts clinical trials that aim to address pressing health challenges, promote innovation, and enhance the well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Makindu, Kenya
Patients applied
Trial Officials
John Vulule, PhD
Principal Investigator
Kenya Medical Research Institute
Ellen Yard, PhD
Principal Investigator
U.S. Centers for Disease Control and Prevention
Johnni Daniel, MPH
Principal Investigator
U.S. Centers for Disease Control and Prevention
Timothy Philips, PhD
Principal Investigator
Texas A&M University
Samuel Amwayi, MD
Principal Investigator
Kenya Ministry of Public Health and Sanitation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials